At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Not Yet Opened 06-23 16:00:00 EDT
513.43
+0.55
+0.11%
盘后513.43
+0.000.00%
17:39 EDT
High522.00Low507.57Vol266.38K
Open513.36D1 Closing512.88Amplitude2.81%
Mkt Cap11.84BTradable Cap5.65BTotal Shares23.06M
T/O136.80MT/O Rate2.42%Tradable Shares11.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Madrigal Pharmaceuticals grants 1,397 inducement RSUs to five new employees under 2025 plan
Reuters  ·  06-23 04:05
Madrigal Pharmaceuticals grants 1,397 inducement RSUs to five new employees under 2025 plan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-23 04:05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  06-23 04:05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals adopts nonqualified deferred compensation plan effective Aug. 1
Reuters  ·  06-18
Madrigal Pharmaceuticals adopts nonqualified deferred compensation plan effective Aug. 1
Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities
Dow Jones  ·  06-11
Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities
BofA Securities Adjusts Madrigal Pharmaceuticals Price Target to $542 From $550
MT Newswires Live  ·  06-11
BofA Securities Adjusts Madrigal Pharmaceuticals Price Target to $542 From $550
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Rezdiffra Data And Analyst Upgrades
Simply Wall St.  ·  06-06
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Rezdiffra Data And Analyst Upgrades
Madrigal grants 6,881 inducement RSUs to 20 new employees under 2025 plan
Reuters  ·  06-05
Madrigal grants 6,881 inducement RSUs to 20 new employees under 2025 plan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  06-05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals (MDGL) Is Down 7.5% After New Rezdiffra MASH Cardiometabolic Data Release – Has The Bull Case Changed?
Simply Wall St.  ·  06-04
Madrigal Pharmaceuticals (MDGL) Is Down 7.5% After New Rezdiffra MASH Cardiometabolic Data Release – Has The Bull Case Changed?
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
GlobeNewswire  ·  06-03
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
Madrigal CMO David Soergel disposes of 1,042 common shares worth $516,763.08
Reuters  ·  06-02
Madrigal CMO David Soergel disposes of 1,042 common shares worth $516,763.08
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Phase 3 And Real World Rezdiffra MASH Data
Simply Wall St.  ·  05-29
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Phase 3 And Real World Rezdiffra MASH Data
Analyst Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target on Strengthened Rezdiffra MASH and Cardiometabolic Data
TIPRANKS  ·  05-28
Analyst Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target on Strengthened Rezdiffra MASH and Cardiometabolic Data
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients With Mash
THOMSON REUTERS  ·  05-27
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients With Mash
Analysts Are Bullish on Top Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Edgewise Therapeutics (EWTX)
TIPRANKS  ·  05-26
Analysts Are Bullish on Top Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Edgewise Therapeutics (EWTX)
Madrigal director Richard S. Levy disposes of USD 2.4 million common shares
Reuters  ·  05-23
Madrigal director Richard S. Levy disposes of USD 2.4 million common shares
Madrigal Pharmaceuticals grants 5,308 inducement RSUs to 15 new employees
Reuters  ·  05-22
Madrigal Pharmaceuticals grants 5,308 inducement RSUs to 15 new employees
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  05-22
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--